<span item_type="fundamental" item_id="20845d644a7ac663000568fb2da505d0" counter_id="ST/US/AVTR" env="prod"></span><span item_type="announcement" item_id="544581881616734593" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 1.683 B, beating the estimate of USD 1.675 B.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.09, missing the estimate of USD 0.1439.</p><p>EBIT: As of FY2025 Q2, the actual value is USD 128.8 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Laboratory Solutions</strong>: Net sales were $1,122.1 million, a reported decrease of 3% compared to $1,155.7 million in the second quarter of 2024. Organic sales declined by 1% after accounting for a 2% positive impact from foreign currency translation and a 4% negative impact from M&amp;A.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li><li><strong>Bioscience Production</strong>: Net sales were $561.3 million, a reported increase of 3% compared to $547.1 million in the second quarter of 2024. Organic sales increased by 2% after a 1% positive impact from foreign currency translation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income</strong>: Decreased to $64.7 million from $92.9 million in the second quarter of 2024, with a net income margin of 3.8%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li><li><strong>Adjusted EBITDA</strong>: $279.8 million, with an adjusted EBITDA margin of 16.6%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li><li><strong>Adjusted Operating Income</strong>: $252.2 million, with an adjusted operating income margin of 15.0%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: $154.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li><li><strong>Free Cash Flow</strong>: $125.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Adjusted Net Leverage</strong>: 3.2x as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>Avantor, Inc. remains focused on driving growth and enhancing operating leverage, with initiatives in place to mitigate challenges in the Bioscience Production segment. The company is optimistic about the strength of its core monoclonal antibody platform and its ability to deliver long-term shareholder value through operational excellence and strong customer relationships.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1722482/000172248225000188/a2025q2earningsreleaseex991.htm"></span></p>

Avantor | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 1.683 B